Introduction
Worldwide, cigarette smoking is a life-style habit of approximately 1.1 billion individuals 52 and is associated with more than six million deaths annually [1] . The immunological 53 responses in persons chronically exposed to smoke from cigarette are characterized by 54 protracted secretion of inflammatory factors and by accumulation of several leukocytes in 55 lung tissue and production of pro-fibrotic mediators such as transforming growth factor 56 (TGF)-β [2, 3] . These inflammatory perturbances likely result in increased risk 57 development of tobacco associated morbidity including several types of cancer [4] , 58 autoimmune disorders [5] , chronic obstructive pulmonary diseases [6] and respiratory 59 infections [7] . 60 
61
The role of tobacco smoking in the induction of disturbances in cell/tissue homeostasis 62 and gene mutations, broadly or specifically associated with several types of tumors, have 63 been investigated. Smoking-related malignancies have been reported to be associated 64 with DNA methylation [8] and mutations in several proto-oncogenes, such as p53, KRAS, 65 BRCA-1, GPX2, GABP, TCF3, CRX, CYP2A13, CYP2A6, CYP2B6, among 66 others [9] [10] [11] [12] . In addition, it has also been reported that components of cigarette smoking 67 modulate immune cell functions, which could lead to loss of T-cell proliferation and 68 antibody responses [13] . Furthermore, chromosomal instability, epigenomic alterations 69 and several mutations have been reportedly associated with lung cancer in particular [14] . 70 Thus, in general, all of these events ultimately culminate with altered gene expression, 71 even though the conversion of carcinogens to DNA adducts is more efficient in some 72 individuals than in others [15] . Therefore, understanding the expression of these gene is 4 73 important to fully understand the link between smoking exposure and risk of cancer 74 development. 75 76 Identification of genetic markers predictive of cancer development is of utmost importance 77 for promoting personalized medicine [16] . Such markers could be implemented as 78 screening strategy for patients who exhibit strong risk factors for cancer, such as cigarette 79 smoking. To identify such potential markers, we performed a systematic analysis of 80 publicly available data from transcriptomic studies performed in lung tissue and/or cells 81 and found that, among most of the studies investigated, increased expression of the gene 82 AKR1B10 was strongly associated with cigarette smoking as well as lung cancer. 83 Development of a point-of-care assay to assess AKR1B10 expression in individuals 84 exposed to cigarette smoking may serve as a relevant tool to identify those with high risk 85 of cancer.
86

Methods
88
Ethics Statement
89
There were no patients directly involved in the research. The present study used 90 publicly available gene expression data from previous studies to perform a meta-91 transcriptome analysis. All information given to the research team were de-identified. brushing. In addition, these studies used a similar transcriptional protocol using the 107 platform Affymetrix Array, making possible to combine both datasets in a discovery set.
108
In silico validation 110 We next performed validation of the differentially expressed genes detected in the first 111 phase of the investigation using three distinct datasets selected by examination of gene 112 expression by smoking status: (i) GSE20257 was published by Shaykhievet a l [19] . In this 113 study, they used samples of small airway epithelium collected from individuals who were 114 smokers (n=51) and also from those who did not smoke (n=42) and performed an analysis who were not exposed to cigarette smoking. the gplots package, using the "scale = "row" switch to Z-score standardize the rows [31] . (NES) (Figure 2A ). The first module (M2), found to be enriched in non-smokers was 192 Glycosaminoglycan biosynthesis chondroitin (log10 p = 1.57 considered together, such pathways were not able to cluster smokers and non-smokers 199 separately ( Figure 2C ). Area under the curve [AUC]: 0.862, p<0.0001; GSE17905 AUC: 0.864, p<0.0001). The 216 same approach indicated that when a dataset from alveolar macrophages was 217 considered, the 22-gene signature was not able to distinguish the study groups 218 (GSE13931AUC: 0.607, p=0.150) ( Figure 3A) . We next employed a machine-learning 219 approach using decision trees to identify which markers from the 22-gene signature would 220 exhibit more robust discrimination power in each dataset evaluated. Of note, the gene 221 AKR1B10 was the most informative gene in the discovery set and also in the two distinct 222 datasets that used large or small airway tissue ( Figure 3B ). In the dataset that used gene 223 expression values form alveolar macrophages, AKR1B10 was not shown to be relevant 224 in discrimination, and a combination of two other genes (VGLL3 and TAS2R10) 225 accounted for the differences between smokers and non-smokers ( Figure 3B ). AKR1B10 226 expression was higher in smokers compared to non-smokers in all datasets evaluated, 227 except again in the GSE13931, which used data on alveolar macrophages ( Figure 3C ). 228 Furthermore, we plotted Venn diagrams of all the DEGs between smokers and non-229 smokers in each dataset to verify overlaps. We confirmed that AKR1B10 was a DEG 230 commonly shown in the discovery set as well as in the databanks which used airway 231 tissue samples, but not in the alveolar macrophage dataset ( Figure 3D ). The two other 232 DEGs found in smokers were CYP1A1 and HS3ST3A1 ( Figure 3D ). discovery analyses were used to validate discrimination between smokers and nonsmokers in 3 239 different previously published datasets. (B) Machine-learning decision trees were built for each dataset 240 to describe the most relevant genes driving discrimination. Of note, the gene AKR1B10 was found to 241 be the main discriminator in 3 out of the 4 datasets examined. AKR1B10 is able to discriminate lung cancer patients who do not smoke 247 The results described above demonstrate that higher AKR1B10 expression hallmarks 248 tissue airways from smokers. Given that smoking is a well-established risk factor of lung 249 cancer[9], we hypothesized that AKR1B10 gene expression could also be useful in 250 identification of cancer patients who were not exposed to smoking. To test this 251 hypothesis, we downloaded the dataset GSE19804, which included tissue samples from 252 non-small cell lung cancer as well as ipsilateral healthy lung tissue obtained from patients 253 who did not present history of cigarette smoking. The AKR1B10 gene expression was 254 substantially higher in the specimen collected from the tumor compared to the healthy 255 lung tissue in the same patients ( Figure 4A ). ROC curve analysis indicated that AKR1B10 256 gene expression value was able to discriminate cancer and non-cancer tissue with 257 relative high accuracy (AUC 0.80, p<0.0001) ( Figure 4B ). high accuracy to discriminate cancer tissue from controls.
Distribution of Single Nucleotide Polymorphisms of AKR1B10, of lung cancer
266 incidence and of deaths attributed to tobacco worldwide 267 We next searched for all the single nucleotide polymorphisms (SNPs) of AKR1B10 that 268 have been published so far and found 11, which have been specific in the gene region 269 ( Figure 5A ). The allele I was denominated the normal nucleotide whereas allele II was 270 the SNP. In Europe, Asia and in the American continents, the most frequent mutant allele 271 was rs782881 (48%, 54% and 42% of the population from these continents, respectively) 272 ( Figure 5A ). In Africa, the most common mutant allele was rs782510 (78% of the 273 population Figure 5A ). Of note, analysis of two SNPs rs782510 and rs782881 with Importantly, when lung cancer incidence in 2018 in both sexes was ranked by continent, 286 we observed that Asia accounted for the majority of cases, followed by Europe and North 287 America, whereas incidence of lung cancer in the African continent was relatively low 288 ( Figure 5B ). Finally, while assessing the Global Burden of Disease dataset [37] we found 289 that these three continents had increased share of cancer deaths attributable tobacco 290 whereas this variable was less representative in the African continent ( Figure 5C ).
291
Discussion 293 In the present study, we examined a number of publicly available transcriptome data to 294 identify a gene signature that could distinguish lung tissue specimens from smokers vs. 295 non-smoking individuals. The most relevant finding of the initial part of analyses was the 296 AKR1B10 expression level was the most informative in such discrimination among three 297 different datasets obtained from lung tissue, but not in the transcriptome data originated 298 from alveolar macrophages. Moreover, AKR1B10 gene expression level was able to 299 reliably identify neoplastic from healthy lung tissue in persons not exposed to cigarette 300 smoking. These findings are important because they have identified AKR1B10 as a 301 reliable biomarker which expression is triggered by cigarette smoking and is 302 simultaneously observed in lung cancer specimens. It is possible that such gene may be 303 involved in carcinogenesis associated with cigarette smoking. In fact, among the multiple 304 carcinogens from cigarette smoke, the nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-305 butanone (NNK) is described to play a critical role in lung carcinogenesis [38] . Carbonyl 306 reduction takes place in both microsomal and cytosolic fractions from different human 307 tissues such as lung and liver [39] . Within these subcellular fractions, several enzymes 308 have been described to mediate NNK reduction, including the protein encoded by 309 AKR1B10, which is from the aldo-keto reductase superfamily (AKR) [40] . Our findings not 310 only confirm an association between AKR1B10 and occurrence of lung cancer but also 311 argues that expression of such gene may occur before onset of neoplastic lesions in 312 smokers and may be suitable to be used for assessment of risk of cancer in highly 313 exposed individuals. Additional studies are warranted to directly test this hypothesis. 314 The gene AKR1B10 found differentially expressed in lung tissue from smokers vs. non-316 smokers has been previously described in experimental studies to play an important role 317 in the pathophysiology of lung cancer [41] . AKR1B10 is a regulator of the synthesis of 318 fatty acid and participates in the metabolic pathway of lipids and isoprenoids [42] . data collection and analysis, decision to publish, or preparation of the manuscript. 399 11. Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem
